Last reviewed · How we verify
PegIFN alfa-2a
PegIFN alfa-2a is a pegylated interferon alpha-2a that activates innate immune responses by binding to interferon-alpha receptors on immune cells.
PegIFN alfa-2a is a pegylated interferon alpha-2a that activates innate immune responses by binding to interferon-alpha receptors on immune cells. Used for Chronic hepatitis C, Chronic hepatitis B.
At a glance
| Generic name | PegIFN alfa-2a |
|---|---|
| Also known as | Pegasys, peginterferon alfa-2a, Pegasys® |
| Sponsor | The Second Affiliated Hospital of Chongqing Medical University |
| Drug class | Pegylated interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology |
| Phase | FDA-approved |
Mechanism of action
Pegylation extends the half-life of interferon alfa-2a by conjugating polyethylene glycol to the protein, allowing less frequent dosing. The drug binds to type I interferon receptors on immune cells, enhancing antiviral and antiproliferative activities. It stimulates natural killer cells, macrophages, and cytotoxic T lymphocytes to combat viral infections and abnormal cell growth.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression
- Injection site reactions
- Anemia
Key clinical trials
- Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy (PHASE4)
- Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B (PHASE2)
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC) (PHASE3)
- A Study in Healthy Volunteers and Patients With Chronic Hepatitis B (PHASE1)
- The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg (PHASE4)
- The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg (PHASE4)
- Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II (PHASE2)
- Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PegIFN alfa-2a CI brief — competitive landscape report
- PegIFN alfa-2a updates RSS · CI watch RSS
- The Second Affiliated Hospital of Chongqing Medical University portfolio CI